Osteoporosis and Zeolite
Excerpt from "Treatment of osteoporosis with a modified zeolite shows beneficial effects in osteoporotic trials..."
The severity of osteoporosis in humans manifests in its high incidence and by its complications that diminish quality of life. A societal consequence of osteoporosis is the substantial burden that it inflicts upon patients and their families.
Osteoporosis and osteoarthritis are common chronic diseases that reduce quality of life and carry a substantial financial burden. Despite pharmacological advances, the burden of osteoporosis remains problematic and current pharmacotherapies often come with adverse side effects.
Here, we present an innovative and cost-effective approach for treating osteoporosis based on studies with an animal model of osteoporosis and a first in human clinical trial. The approach takes advantage of properties exhibited by zeolites, particularly Panaceo Micro Activation (PMA)-clinoptilolite, a surface modified zeolite with ion exchange properties. Intervention of osteoporotic animals and patients with PMA-zeolite-clinoptilolite yielded sufficient beneficial markers of bone formation and maintenance of bone integrity to warrant further evaluation of this compound, alone or in combination with a current therapy, for the treatment of osteoporosis.
To view the original study, [Treatment of osteoporosis with a modified zeolite shows beneficial effects in an osteoporotic rat model and a human clinical trial], click here.